Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression. Onda N, Nakamichi S, Hirao M, Matsuda K, et al. Cancer Sci 2024;115:2718-2728.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Onda N, Nakamichi S, Hirao M, Matsuda K, et al. Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression. Cancer Sci 2024;115:2718-2728.
PMID: 38941131